Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1039-1044

  Yoon, D H ^a   Ryu, M H ^a   Park, Y S ^a   Lee, H J ^a   Lee, C ^a   Ryoo, B Y ^a   Lee, J L ^a   Chang, H M ^a   Kim, T W ^a   Kang, Y K ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

advanced gastric cancer; biomarker; everolimus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXIFLURIDINE; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; INITIATION FACTOR 4E BINDING PROTEIN 1; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PLATINUM; S6 KINASE; STEROID; UFT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INOPERABLE CANCER; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG HEMORRHAGE; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; VIRUS INFECTION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT DROPOUTS; PLATINUM COMPOUNDS; SIROLIMUS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84862824218     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.47     Document Type: Article

References (16)

1. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5): 335-348 (Pubitemid 38579480)
2. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107(8): 1801-1811 (Pubitemid 44582949)
3. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M (2007) Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 5(6): 379-385 (Pubitemid 47584475)
4. Ciuffreda L, Di Sanza C, Incani UC, Milella M (2010) The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 10(5): 484-495
5. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R (2009) Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res 15(1): 217-225
6. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28(11): 1904-1910
7. Dufner A, Andjelkovic M, Burgering BM, Hemmings BA, Thomas G (1999) Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol Cell Biol 19(6): 4525-4534 (Pubitemid 29242025)
8. El-Salem M, Raghunath PN, Marzec M, Wlodarski P, Tsai D, Hsi E, Wasik MA (2007) Constitutive activation of mTOR signaling pathway in posttransplant lymphoproliferative disorders. Lab Invest 87(1): 29-39 (Pubitemid 44973651)
9. Frattini M, Signoroni S, Pilotti S, Bertario L, Benvenuti S, Zanon C, Bardelli A, Pierotti MA (2005) Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res 65(23): 11227 (Pubitemid 41713394)
10. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS (2008) Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21(3): 231-237 (Pubitemid 351304283)
11. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14): 2137-2150 (Pubitemid 46655601)
12. Kang YK, Yoon DH, Ryoo BY, Ryu MH (2010) Recent advances in chemotherapy for advanced gastric cancer. Asia-Pacific J Oncol Hematol 2(1): 67-74
13. Lee JL, Ryu MH, Chang HM, Kim TW, Yook JH, Oh ST, Kim BS, Kim M, Chun YJ, Lee JS, Kang YK (2008) A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 61(4): 631-637
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. The Lancet 372(9637): 449-456
15. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108 (Pubitemid 40372904)
16. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz Jr S, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41(11): 1649-1654 (Pubitemid 40981849)